Connecticut SB 241: AN ACT CONCERNING THE OFFICE OF HEALTH STRATEGY'S RECOMMENDATIONS REGARDING 340B PROGRAM TRANSPARENCY.

Bill Text

LCO No. 1536 1 of 2

General Assembly Raised Bill No. 241
February Session, 2024 LCO No. 1536

Referred to Committee on PUBLIC HEALTH

Introduced by:
(PH)

AN ACT CONCERNING THE OFFICE OF HEALTH STRATEGY'S
RECOMMENDATIONS REGARDING 340B PROGRAM
TRANSPARENCY.
Be it enacted by the Senate and House of Representatives in General
Assembly convened:

Section 1. (NEW) (Effective October 1, 2024) (a) As used in this section, 1
(1) "federal 340B Drug Pricing Program" or "program" means the plan 2
described in Section 340B of the Public Health Service Act, 42 USC 256b, 3
as amended from time to time, and (2) "340B covered entity" means an 4
entity authorized to participate in the federal 340B Drug Pricing 5
Program under 42 USC 256b(a)(4), as amended from time to time. 6
(b) Not later than April 1, 2025, and annually thereafter, each 340B 7
covered entity shall report to the Health Systems Planning Unit of the 8
Office of Health Strategy, in a form and manner prescribed by the 9
executive director of the Office of Health Strategy, information 10
regarding such entity's participation in the federal 340B Drug Pricing 11
Program. Such report shall include the (1) aggregated acquisition cost 12
for prescription drugs obtained under the program, (2) aggregated 13
payment amount received for prescription drugs obtained for and 14

Raised Bill No. 241

LCO No. 1536 2 of 2

dispensed to patients under the program, (3) aggregated payments 15
made to pharmacies under contract to dispense prescription drugs 16
obtained under the program, (4) number of claims for prescription 17
drugs described in subdivision (2) of this subsection, and (5) if the 340B 18
covered entity is a hospital licensed pursuant to chapter 368v of the 19
general statutes, the national drug code number for the fifty most 20
frequently dispensed prescription drugs by the hospital under the 21
program. The information required to be reported pursuant to this 22
subsection shall (A) be disaggregated by payer mix, including, but not 23
limited to, Medicare, Medicaid and private insurance, as prescribed by 24
the executive director, and (B) include prescription drugs dispensed by 25
outpatient facilities that are child sites listed as reimbursable facilities 26
on a hospital's Medicare cost report. 27
(c) The executive director of the Office of Health Strategy shall post a 28
summary of the aggregate information received by the unit pursuant to 29
the provisions of this section on the Office of Health Strategy's Internet 30
web site. 31
This act shall take effect as follows and shall amend the following
sections:

Section 1 October 1, 2024 New section

Statement of Purpose:
To require entities authorized to participate in the federal 340B Drug
Pricing Program to report to the Health Systems Planning Unit of the
Office of Health Strategy certain information regarding the program,
including (1) aggregated acquisition costs, (2) aggregated payment
information, (3) the number of claims for prescription drugs under the
program, and (4) if the entity is a hospital, the national drug code
number for the fifty most frequently dispensed prescription drugs by
the hospital under the program.
[Proposed deletions are enclosed in brackets. Proposed additions are indicated by underline, except
that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not
underlined.]